1. Introduction {#sec1-marinedrugs-15-00126}
===============

Cyanobacteria, also known as blue-green algae, including cyanobacteria from terrestrial, freshwater and marine ecosystems, are a group of ancient photosynthetic prokaryotes. As defensive chemicals, structurally-diverse secondary metabolites from cyanobacteria have been proven to greatly contribute to successful survival and reproduction of cyanobacteria in changing, complex and diverse environments during the long-lasting evolutionary process \[[@B1-marinedrugs-15-00126]\]. At present, hundreds of compounds with important bioactivities have been isolated from terrestrial or marine cyanobacteria \[[@B2-marinedrugs-15-00126]\]. Macrolides are a class of important bioactive compounds, which are commonly found in marine organisms, including cyanobacteria \[[@B3-marinedrugs-15-00126]\]. Some marine macrolides are promising candidates for future applications in medicine. For example, bryostatin-1 shows potent antitumor activity in phase I cancer clinical trials \[[@B4-marinedrugs-15-00126]\]. Macrolide antibiotics, such as erythromycin and polyene macrolides, have been employed for widespread application of severe bacterial infections \[[@B5-marinedrugs-15-00126]\]. Structurally-diverse macrolides from cyanobacteria often contain unique and unusual substituents, including chlorinated residues, thiazole residues \[[@B6-marinedrugs-15-00126]\] or pyran residues \[[@B7-marinedrugs-15-00126]\]. Macrolides usually exhibit potent antitumor or antibacterial activities \[[@B8-marinedrugs-15-00126]\]. In addition, cyanobacteria have great potentials as sustainable sources for production of bioactive macrolides because of their rapid growth, genetic tractability and cultivable property \[[@B2-marinedrugs-15-00126]\]. Although cyanobacteria possess cultivable properties similar to those of microorganisms, cyanobacteria have attracted far less attention than microorganisms.

In the present review paper, we systematically summarized the structures and bioactivities of macrolides isolated from cyanobacteria, and over 50 references were cited. Up to the end of 2016, a total of 64 macrolide compounds have been isolated from cyanobacteria, including 49 macrolides from marine cyanobacteria and 15 macrolides from terrestrial cyanobacteria, most of which are mainly from *Lyngbya*, *Scytonema* and *Oscillatoria*. It has been reported that most of these cyanobacterium-derived macrolides possess several noticeable bioactivities, including antitumor, antibacterial, antimalarial and toxicity to animals. This review summarizes new macrolides derived from cyanobacteria, providing useful information in the further discovery of novel cyanobacterial macrolides.

2. Anti-Neoplastic Property of Cyanobacterium-Derived Macrolides on Different Cell Lines {#sec2-marinedrugs-15-00126}
========================================================================================

Nitrogen mustard has been used in the treatment of lymphoma cancer since 1940s, and more than 100 anti-cancer drugs are widely used in the world. Until now, natural products have largely contributed to cancer therapy and become an indispensable source for the development of innovative anti-cancer drugs \[[@B9-marinedrugs-15-00126]\]. Most macrolides from cyanobacteria display significant cytotoxicity to cancer cells. Cyanobacteria of the genera *Symploca*, *Lyngbya*, *Scytonema* and *Oscillatoria* are important sources of anti-cancer macrolides. Cyanobacterium-derived macrolides reported to have anti-neoplastic effects on different cell lines are given in [Figure 1](#marinedrugs-15-00126-f001){ref-type="fig"} and [Table 1](#marinedrugs-15-00126-t001){ref-type="table"}.

A series of cytotoxic marine cyanobacterial metabolites, named lyngbyabellins (**1**--**11**) possessing thiazole residues and chlorine substituents, have been isolated from the cyanobacterial genus *Lyngbya* ([Figure 2](#marinedrugs-15-00126-f002){ref-type="fig"}). Isolated from the marine cyanobacterium *Lyngbya majuscula* collected from Guam, lyngbyabellin A (**1**) exhibits potent in vitro cytotoxicity against human carcinoma of nasopharynx Cell (KB cells) and LoVo cells with IC~50~ values of 0.03 and 0.50 µg/mL, respectively \[[@B6-marinedrugs-15-00126]\]. The analog of lyngbyabellin A (**1**), lyngbyabellin B (**2**), was isolated from the same strain of *Lyngbya majuscula*. Compared with lyngbyabellin A (**1**), lyngbyabellin B (**2**) is slightly less cytotoxic to KB and LoVo cells with IC~50~ values of 0.10 and 0.83 µg/mL, respectively \[[@B10-marinedrugs-15-00126]\]. Five analogs of lyngbyabellin A (**1**), including lyngbyabellins E-I (**3**--**7**), are produced from the same strain of *Lyngbya majuscula* harvested in Papua New Guinea. To the best of our knowledge, lyngbyabellins E-I (**3**--**7**) have potent in vitro cytotoxicity against human lung tumor (NCI-H460) and mouse neuroblastoma (neuro-2a) cells. Lyngbyabellin E (**3**) and lyngbyabellin H (**6**) display significant cytotoxicity to NCI-H460 (LC~50~ values of 0.4 and 0.2 µM, respectively) and neuro-2a cells (LC~50~ values of 1.2 and 1.4 µM, respectively). Lyngbyabellins F-G (**4**--**5**) and lyngbyabellin I (**7**) are slightly less cytotoxic to NCI-H460 (LC~50~ values of 1.0, 2.2 and 1.0 µM, respectively) and neuro-2a cells (LC~50~ values of 1.8, 4.8 and 0.7 µM, respectively) \[[@B11-marinedrugs-15-00126]\]. The marine cyanobacterium *Moorea bouillonii* (formerly *Lyngbya bouillonii*) collected from Palmyra Atoll affords four analogs of lyngbyabellin A (**1**), lyngbyabellins K (**8**), L (**9**), N (**10**) and 7-*epi*-lyngbyabellin L (**11**). Lyngbyabellin N (**10**) shows variable cytotoxicity to H-460 human lung carcinoma (IC~50~ = 0.0048--1.8 μM) and potent in vitro cytotoxicity against the HCT116 colon cancer cell line (IC~50~ = 40.9 ± 3.3 nM). This result could perhaps be explained by the solubility problem of lyngbyabellin N (**10**). The nitrogen-containing side chain (leucine statine residue) of lyngbyabellin N (**11**) may be the basic structural feature for its cytotoxic activity \[[@B12-marinedrugs-15-00126]\].

Several 16-membered glycoside macrolides, termed lyngbyalosides, are produced from various species of the cyanobacterial genus *Lyngbya* ([Figure 3](#marinedrugs-15-00126-f003){ref-type="fig"}). The marine *Lyngbya bouillonii*, collected from Laing Island, afford lyngbyaloside (**12**) \[[@B8-marinedrugs-15-00126]\]. Lyngbyaloside B (**13**), isolated from marine cyanobacterium *Lyngbya* sp., which was collected from Palaua, shows weak cytotoxicity against KB cells and LoVo cells with IC~50~ values of 4.3 and 15 µM, respectively \[[@B13-marinedrugs-15-00126]\]. The total synthesis of lyngbyaloside B (**13**) has been reported by Fuwa et al. \[[@B33-marinedrugs-15-00126]\]. Three analogs of lyngbyaloside (**12**), including 2-*epi*-lyngbyaloside (**14**), 18*E*-lyngbyaloside C (**15**) and 18*Z*-lyngbyaloside C (**16**), were isolated from the marine cyanobacterium *Lyngbya bouillonii*, collected from Apra Harbor, Guam. Cytotoxicity assays revealed that these macrolides possess weak to moderate cytotoxicity against the human colorectal adenocarcinoma cell line HT29 and HeLa cervical carcinoma cells. 18*E*-lyngbyaloside C (**15**) is more cytotoxic toward HT29 colorectal adenocarcinoma and HeLa cervical carcinoma cells (IC~50~ values of 13 and 9.3 µM, respectively) than 2-*epi*-lyngbyaloside (**14**) (IC~50~ values of 38 and 33 µM, respectively). 18*E*-Lyngbyaloside C (**15**) is approximately five-fold more cytotoxic than 18*Z*-lyngbyaloside C (**16**) (IC~50~ values of \>100 µM and 53 µM, respectively) \[[@B14-marinedrugs-15-00126]\]. The total synthesis of lyngbyaloside C has also been accomplished \[[@B34-marinedrugs-15-00126]\].

Another distinct class of 18-membered ring glycoside macrolides has been isolated from the cyanobacterial genus *Lyngbya* ([Figure 4](#marinedrugs-15-00126-f004){ref-type="fig"}). Biselyngbyaside (**17**) was discovered through a bioassay-guided screening for cytotoxic compounds from cyanobacterium *Lyngbya* sp. collected from Okinawa Prefecture, Japan. Biselyngbyaside (**17**) shows a broad spectrum of cytotoxicity against human solid tumor cell lines, especially for HeLa S~3~ cells with an IC~50~ value of 0.1 μg/mL \[[@B15-marinedrugs-15-00126]\], and its total synthesis was completed \[[@B35-marinedrugs-15-00126]\]. Extensive efforts toward finding cytotoxic natural products have resulted in the isolation of three analogs of biselyngbyaside (**17**), named biselyngbyasides B--D (**18**--**20**), from the marine cyanobacterium *Lyngbya* sp. Biselyngbyaside B (**18**) displays significant cytotoxicity against HeLa S~3~ and HL60 cells (IC~50~ values of 3.5 and 0.82 µM, respectively, using thapsigargin as a positive control drug). In addition, biselyngbyasides B-D (**18**--**20**) induced apoptosis of cancer cells by inhibiting calcium influx into the endoplasmic reticulum and increasing the concentration of intracellular calcium \[[@B16-marinedrugs-15-00126]\]. Two analogs of biselyngbyaside (**17**), biselyngbyasides E (**21**) and F (**22**), were isolated from the marine cyanobacterium *Lyngbya* sp. collected from Ishigaki Island, Japan. In vitro cell cytotoxicity assays showed that biselyngbyaside E (**21**) has higher cytotoxicity against HeLa and HL60 cells (IC~50~ values of 0.19 and 0.071 µM, respectively) than biselyngbyaside F (**22**) (IC~50~ values of 3.1 and 0.66 µM, respectively). Based on the trisubstituted olefin geometry, the presence and absence of the sugar moiety are crucial for the biological activities \[[@B17-marinedrugs-15-00126]\].

Like a cytotoxic biselyngbyaside-related macrolide, biselyngbyolide A (**23**) was isolated from the marine cyanobacterium *Lyngbya* sp. harvested from Tokunoshima Island, Japan. Biselyngbyolide A (**23**) shows strong cytotoxicity against HeLa S~3~ cells and HL60 cells with IC~50~ values of 0.22 and 0.027 µM, respectively \[[@B18-marinedrugs-15-00126]\]. Biselyngbyolide B (**24**) was also isolated from the same strain of *Lyngbya* sp. and displays significant inhibitory effects on growth of HeLa S~3~ cells and HL60 cells (IC~50~ values of 0.028 and 0.0027 µM, respectively, using thapsigargin as a positive control drug). Moreover, biselyngbyolide B (**24**) has 3--100-fold more potent apoptosis-inducing activity than biselyngbyaside (**17**) \[[@B16-marinedrugs-15-00126],[@B19-marinedrugs-15-00126]\].

A novel 36-membered macrolactone, caylobolide A (**25**), was isolated from Bahamian cyanobacterium *Lyngbya majuscula*, which contains an unprecedented repeating unit, an adjoining pentad of 1,5-diols and a 1,3,5-triol ([Figure 5](#marinedrugs-15-00126-f005){ref-type="fig"}). In vitro cytotoxicity assay showed that caylobolide A (**25**) possesses potent cytotoxicity against human colon tumor cells HCT-116 with an IC~50~ value of 9.9 µM \[[@B20-marinedrugs-15-00126]\], and its total synthesis has been accomplished \[[@B36-marinedrugs-15-00126]\]. Caylobolide B (**26**) was isolated from the marine cyanobacterium *Phormidium* spp. collected from Key West, Florida, and it exhibits strong cytotoxicity against HT29 colorectal adenocarcinoma (IC~50~ value of 4.5 µM) and HeLa cervical carcinoma cells (IC~50~ value of 12.2 µM) \[[@B21-marinedrugs-15-00126]\].

Swinholide A (**27**), originally isolated from the marine sponge *Theonella swinhoei*, was isolated from the marine cyanobacterium *cf*. *Symploca* sp. collected from Fiji and was found to strongly inhibit the growth of several tumor cell lines with IC~50~ values ranging from 0.37 nM to 1.0 μM \[[@B22-marinedrugs-15-00126]\]. Two swinholide-based glycosylated macrolides, named ankaraholides A,B (**28**,**29**), were isolated from two field collections of marine cyanobacteria ([Figure 6](#marinedrugs-15-00126-f006){ref-type="fig"}). Ankaraholide A (**28**) exhibits strong antiproliferative activity against NCI-H460, Neuro-2a and MDA-MB-435 cell lines with IC~50~ values of 119, 262 and 8.9 nM, respectively. Ankaraholide A (**28**) inhibits proliferation of A-10 cells by inducing complete loss of the filamentous (F)-actin during the cell extending process when the concentration of ankaraholide A (**28**) reaches 30 nM \[[@B22-marinedrugs-15-00126]\].

A family of potent cytotoxic natural products, scytophycins A--E (**30**--**34**), was isolated from the terrestrial cyanobacterium *Scytonema pseudohofmanni* \[[@B37-marinedrugs-15-00126]\]. Scytophycins A (**30**) and B (**31**) display significant cytotoxicity against KB cells (IC~50~ value of 1 ng/mL), while scytophycins C-E (**32**--**34**) are less cytotoxic to KB cells (IC~50~ values ranging from 10 to 100 ng/mL) than scytophycin A (**30**) \[[@B23-marinedrugs-15-00126]\]. Total synthesis of scytophycin C (**32**) has been completed \[[@B38-marinedrugs-15-00126]\]. Screening of cyanobacteria leads to the discovery of three analogs of scytophycins, including 6-hydroxyscytophycin B (**35**), 19-*O*-demethylscytophycin C (**36**) and 6-hydroxy-7-*O*-methylscytophycin E (**37**) ([Figure 7](#marinedrugs-15-00126-f007){ref-type="fig"}). These compounds (**35**--**37**) show strong inhibitory effect on the growth of KB (MIC values ranging from 1 to 5 ng/mL) and LoVo cells (MIC values ranging from 10 to 50 ng/mL) \[[@B23-marinedrugs-15-00126]\]. The cytotoxic tolytoxin (**38**) was isolated from terrestrial cyanobacterium *Tolypothrix conglutinata*, collected from Fanning Island \[[@B39-marinedrugs-15-00126]\], and displays excellent cytotoxicity against LoVo and KB cells with IC~50~ values of 8.4 and 5.3 nM, respectively \[[@B24-marinedrugs-15-00126]\].

Debromoaplysiatoxin (**39**) was isolated from the marine cyanobacterium *Lyngbya majuscula*, collected from Hawaii \[[@B40-marinedrugs-15-00126]\], and shows potent cytotoxicity against mouse lymphocytic leukemia P-388 \[[@B25-marinedrugs-15-00126]\]. Four analogs of debromoaplysiatoxin (**39**), including oscillatoxin A (**40**), 19,21-dibromooscillatoxin A (**41**), 19-bromoaplysiatoxin (**42**) and 21-bromooscillatoxin A (**43**), were isolated from a mixture of marine cyanobacteria *Oscillatoria nigroviridis* and *Schizothrix calcicola* from Enewetak Island ([Figure 8](#marinedrugs-15-00126-f008){ref-type="fig"}). These compounds (**41**--**43**) contain the same 14-membered macrocycle as debromoaplysiatoxin (**39**), but they are bromine-containing macrolides \[[@B41-marinedrugs-15-00126]\]. A 14-membered glycosidic macrolide, lyngbouilloside (**44**), was isolated from the marine cyanobacterium *Lyngbya bouillonii*, harvested from Papua New Guinea. It displays a modest cytotoxicity against neuroblastoma cells with an IC~50~ value of 17 µM \[[@B26-marinedrugs-15-00126]\]. Another 14-membered macrolide, koshikalide (**45**), was isolated from the marine cyanobacterium *Lyngbya* sp., collected from Mie Prefecture, Japan, and shows slight cytotoxicity against HeLa S~3~ cells with an IC~50~ value of 42 µg/mL \[[@B27-marinedrugs-15-00126]\]. In addition, the total synthesis of koshikalide (**45**) has been achieved by exploiting a novel convergent strategy \[[@B42-marinedrugs-15-00126]\]. A 14-membered marine macrolide, sanctolide A (**46**), containing a rare *N*-methyl enamide and a 2-hydroxyisovaleric acid, was obtained from the culture of cyanobacterium *Oscillatoria sancta*. It is cytotoxic against HT-29 and MDA-MB-435 cell lines \[[@B28-marinedrugs-15-00126]\], and its total synthesis was achieved \[[@B43-marinedrugs-15-00126]\].

Two cytotoxic marcolides, acutiphycin (**47**) and 20,21-didehydroacutiphycin (**48**), were isolated from freshwater cyanobacterium *Oscillatoria acutissima*, collected from Manoa Valley, Oahu, and possess strong cytotoxicity against KB and NIH/3T3 cells (ED~50~ \< 1 μg/mL), as well as Lewis lung carcinoma \[[@B29-marinedrugs-15-00126]\]. A rare marine toxin, polycavernoside D (**49**), was obtained from the marine *Okeania* sp. collected from the Caribbean ([Figure 9](#marinedrugs-15-00126-f009){ref-type="fig"}). The discovery of polycavernoside D, for the first time, provides a conclusive proof that these lethal toxins (polycavernosides) have, in fact, a cyanobacterial origin rather than other marine organisms. Polycavernoside D (**49**) displays cytotoxicity against the H-460 human lung cancer cell line in a dose-dependent manner, with an EC~50~ value of 2.5 µM \[[@B30-marinedrugs-15-00126]\]. Bastimolide A (**50**), isolated from the marine *Okeania hirsuta* from Bastimentos Park, Panama, is a rare 40-membered polyhydroxy macrolide consisting of one 1,3-diol, one 1,3,5-triol, six 1,5-diols and one *tert*-butyl group. Bastimolide A (**50**) exhibits strong cytotoxicity against Vero cells with an IC~50~ value of 2.1 µM \[[@B31-marinedrugs-15-00126]\].

A rare 40-membered macrolactone, nuiapolide (**51**), was isolated from Niihau marine cyanobacterium. As a polyhydroxylated macrolide, nuiapolide (**51**) contains a rare *tert*-butyl carbinol residue, and it displays anti-chemotactic activity against Jurkat cells and cancerous T lymphocytes and can trigger a predominant G2/M phase shift in the cell cycle \[[@B32-marinedrugs-15-00126]\].

3. Antibacterial Activity {#sec3-marinedrugs-15-00126}
=========================

Some macrolides, such as erythromycin and azithromycin, have shown excellent antibacterial activity and are widely used in clinical practice of various types of bacterial infections \[[@B44-marinedrugs-15-00126]\]. Some macrolides from cyanobacteria also show good antibacterial activities. Cyanobacterium-derived macrolides with antimicrobial properties are listed in [Table 2](#marinedrugs-15-00126-t002){ref-type="table"}.

Scytophycins C--E (**32**--**34**) were isolated from the terrestrial cyanobacterium *Scytonema pseudohofmanni*, collected from Oahu, Hawaii, and were shown to exhibit weak antibacterial activity \[[@B37-marinedrugs-15-00126]\]. Three analogs of scytophycin C (**32**), including 6-hydroxyscytophycin B (**35**), 19-*O*-demethylscytophycin C (**36**) and 6-hydroxy-7-*O*-methylsctophycin E (**37**), were isolated from the cyanobacteria *S*. *mirabile*, *S*. *burmanicurn* and *S*. *ocellatum*, respectively. These macrolides (**35**--**37**) display antifungal activity against *Aspergillus oryzae*, *Candida albicans*, *Penicillium notatum* and *Saccharomyces cerevisiae* \[[@B23-marinedrugs-15-00126]\]. The cytotoxin, tolytoxin (**38**), was isolated from the terrestrial cyanobacterium *Tolypothrix conglutinata*, collected from Fanning Island \[[@B39-marinedrugs-15-00126]\], and was found to exhibit potent antifungal activity against various yeasts and filamentous fungi (MICs of 0.25--8 nM) \[[@B24-marinedrugs-15-00126]\].

A bioactive marcolide, 7-OMe-scytophycin B (**52**), was identified from a culture of a marine cyanobacterium and was found to exhibit antifungal activity against *Candida albicans* HAMbI 484 and *Candida guilliermondii* HAMBI 257 with MIC values of 0.40 and 0.80 mM and IC~50~ values of 0.19 and 0.23 mM, respectively \[[@B45-marinedrugs-15-00126]\]. Two 40-membered macrolactones, amantelides A,B (**53**,**54**), are composed of a 1,3-diol and contiguous 1,5-diol units and a *tert*-butyl substituent. These compounds were isolated from a Guam cyanobacterium belonging to the family Oscillatoriales ([Figure 10](#marinedrugs-15-00126-f010){ref-type="fig"}). Amantelide A (**53**) shows a broad spectrum of inhibitory effects on the growth of both eukaryotic and prokaryotic cells. The growth of the fungi *Lindra thalassiae* and *Fusarium* sp. is completely inhibited when the concentration of amantelide A (**53**) is 62.5 μg/mL. When the concentration of amantelide B (**54**) is 6.25 μg/mL, the growth of the fungus *Dendryphiella salina* is completely inhibited \[[@B46-marinedrugs-15-00126]\].

4. Effects of Cyanobacterium-Derived Macrolides on Animals {#sec4-marinedrugs-15-00126}
==========================================================

Toxin-producing cyanobacterial blooms are a potential health risk for other living organisms, including humans \[[@B47-marinedrugs-15-00126]\]. Cyanobacterium-derived macrolides show toxicity to animals, such as brine shrimp and mice. The effects of cyanobacterium-derived macrolides on fauna are described in [Table 3](#marinedrugs-15-00126-t003){ref-type="table"}.

The cytotoxic macrolactone, lyngbyabellin A (**1**), exhibits potent toxicity to mice in vivo trials (lethal dose of 2.4 to 8.0 mg/kg; sublethal dose of 1.2 to 1.5 mg/kg) \[[@B6-marinedrugs-15-00126]\]. Tolytoxin (**38**) is highly toxic to mice with a sublethal dose (ip) of 1.5 mg /kg \[[@B24-marinedrugs-15-00126]\].

A 14-membered macrolide, sanctolide A (**48**), shows high toxicity toward the brine shrimp with an LC~50~ value of 23.5 μM \[[@B28-marinedrugs-15-00126]\]. A 10-membered ring macrolide, gloeolactone (**55**), was isolated from the cyanobacterium *Gloeotrichia* sp., harvested in Clark Canyon Reservoir ([Figure 11](#marinedrugs-15-00126-f011){ref-type="fig"}). Gloeolactone (**55**) exhibits weak toxicity to brine shrimp. All brine shrimps are dead when the concentration of gloeolactone (**55**) is 125 μg/mL \[[@B48-marinedrugs-15-00126]\]. Phormidolide (**56**) was isolated from the marine cyanobacterium *Phormidium* sp. cultured in Indonesia and was found to exhibit very high toxicity (LC~50~ value of 1.5 μM) in the brine shrimp test \[[@B49-marinedrugs-15-00126]\].

A symmetrical macrolide dimer, cyanolide A (**57**), was obtained from the marine cyanobacterium *Lyngbya bouillonii* collected from Papua New Guinea. Cyanolide A (**57**) displays potent molluscicidal activity against the snail vector *Biomphalaria glabrata* with an LC~50~ value of 1.2 µM. Cyanolide A (**57**) can be used as a new, potent molluscicidal agent to effectively control the spread of schistosomiasis \[[@B50-marinedrugs-15-00126]\]. Its total synthesis has been accomplished \[[@B51-marinedrugs-15-00126]\].

5. Other Bioactivity {#sec5-marinedrugs-15-00126}
====================

Cyanobacterium-derived macrolides with rich chemical diversity show various important bioactivities ([Table 4](#marinedrugs-15-00126-t004){ref-type="table"}). The macrolide biselyngbyaside (**17**), isolated from the marine cyanobacterium *Lyngbya* sp., has been investigated for its effects on osteoclast differentiation and function. Biselyngbyaside (**17**) inhibits RANKL-induced osteoclastogenesis by inhibiting the expression of c-Fos and NFATc1 in mouse monocytic RAW264 cells. Therefore, biselyngbyaside (**17**) is a potentially promising compound with therapeutic and preventive activities against bone-lytic diseases \[[@B52-marinedrugs-15-00126]\]. A toxic cyanobacterial macrolide, debromoaplysiatoxin (**39**), has been found to cause severe cutaneous inflammation in humans and other animals after topical application \[[@B25-marinedrugs-15-00126]\].

A rare 40-membered polyhydroxy macrolide, bastimolide A (**50**), exhibits high selectivity and antimalarial activity against four drug-resistant malaria parasite strains, including TM90-C2A, TM90-C2B, W2 and TM91-C235, with IC~50~ values of 80, 90, 140 and 270 nM, respectively. It has been proven that bastimolide A (**50**) is a potentially promising antimalarial lead compound with high selectivity and antimalarial activity against drug-resistant strains \[[@B31-marinedrugs-15-00126]\]. Malyngolide dimer (**58**) was isolated from the marine cyanobacterium *Lyngbya majuscula* collected from Panama and was shown to exhibit moderate antimalarial activity against chloroquine-resistant *Plasmodium falciparum* (W2) with an IC~50~ value of 19 µM \[[@B53-marinedrugs-15-00126]\].

A novel SIRT2-selective inhibitor, tanikolide dimer (**59**), was isolated from marine cyanobacterium *Lyngbya majuscula* collected from Madagascar, and it possesses a symmetrical dimer, which has been elucidated by comparison of the natural and synthetic stereoisomers using chiral GC-MS ([Figure 12](#marinedrugs-15-00126-f012){ref-type="fig"}). The tanikolide dimer (**59**) is a potent and selective SIRT2 inhibitor with an IC~50~ value of 176 nM \[[@B54-marinedrugs-15-00126]\].

An unusually stabilized neuroactive macrolide, palmyrolide A(**60**), was isolated, via an assay-based screening program for new neuroactive compounds from cyanobacteria *Leptolyngbya cf.* and *Oscillatoria* spp. harvested in Palmyra Atoll. Palmyrolide A (**60**) contains a rare *N*-methyl enamide and an intriguing *tert*-butyl group, and it can potently inhibit Ca^2+^ oscillations in murine cerebrocortical neuronal cells with an IC~50~ value of 3.70 µM. Moreover, palmyrolide A (**60**) can significantly block the sodium channel activity of neuro-2a cells (IC~50~ value of 5.2 µM) without appreciable cytotoxicity. The above intriguing experimental results suggest that palmyrolide A (**60**) could be a promising drug candidate for further pharmacological exploration \[[@B55-marinedrugs-15-00126]\], and its total synthesis has been completed \[[@B56-marinedrugs-15-00126]\].

A dimeric macrolide, cocosolide (**61**), was isolated from the marine cyanobacterium *Symploca* sp. from Guam, and it strongly inhibits IL-2 production in both T-cell receptor-dependent and independent manners. Both the presence of the sugar moiety and the integrity of the dimeric structure ensure the functionality of cocosolide (**61**). In addition, the total synthesis of cocosolide (**61**) has been accomplished \[[@B7-marinedrugs-15-00126]\].

Three novel nitrogen-containing macrolides, laingolide (**62**) \[[@B57-marinedrugs-15-00126]\], laingolide A (**63**) and madangolide (**64**) \[[@B58-marinedrugs-15-00126]\], have been identified from the marine cyanobacterium *Lyngbya bouillonii* harvested in Laing Island, Papua-New Guinea ([Figure 12](#marinedrugs-15-00126-f012){ref-type="fig"}). The structures of these macrolides (**62--64**) contain a lactone ring of 15, 15 and 17 members, respectively \[[@B58-marinedrugs-15-00126]\].

6. Conclusions {#sec6-marinedrugs-15-00126}
==============

Cyanobacteria are rich sources of various natural products with unprecedented pharmacological and biological activities. Up to the end of 2016, a total of 64 macrolide compounds have been isolated from cyanobacteria, including 49 macrolides from marine cyanobacteria and 15 macrolides from terrestrial cyanobacteria. More than half of the cyanobacterium-derived macrolides, a total of 36 compounds, were isolated from the cyanobacterial genus *Lyngbya* species, particularly from *Lyngbya majuscula*. Most of these cyanobacterium-derived macrolides possess several noticeable bioactivities, including antitumor, antibacterial and antimalarial. The overwhelming majority of cyanobacteria derived macrolides (**1**--**51**) display in vitro antitumor activity. Secondary metabolites of cyanobacteria are widely evaluated for their antitumor effects since many metabolites of cyanobacteria have exhibited potent antitumor activities. Some of these macrolides, including tolytoxin (**38**), bastimolide A (**50**) and tanikolide dimer (**59**), exhibited surprisingly strong bioactivity, thus representing potential new drug lead compounds, which are worthy of further research on synthesis and pharmacological activity. The total synthesis of 10 bioactive macrolides, such as cocosolide, has been achieved with a great deal of efforts. The research on the total synthesis of macrolides will promote pharmacologic research and create new opportunities to undertake research in drug discovery, medicine design and large-scale manufacturing. At present, three scholars, including Luesch, Moore and Gerwick, have greatly contributed to the discovery of new macrolides from cyanobacteria. Cyanobacteria have great potentials as sustainable sources for the production of bioactive metabolites because of their rapid growth, genetic tractability and cultivable property. Although cyanobacteria possess the cultivable properties similar to those of microorganisms, cyanobacteria have attracted far less attention than microorganisms. More efforts should be devoted to improving the production of bioactive metabolites in cyanobacteria via cultivation design, metabolic engineering together with efficient isolation. In addition, the programs for drug discovery from cyanobacteria, including the Panama International Cooperative Biodiversity Group (ICGB) program, might facilitate and enhance drug discovery from cyanobacteria. A systematic review on macrolides from cyanobacteria would help establish an effective support system for the discovery and development of cyanobacterium-derived macrolides, and such a support system could also facilitate collection, purification and identification of bioactive macrolides, leading to improve bioactivity assay, synthesis, data analysis and information technology.
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Chemical structures of Compounds **1**--**11**.
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Chemical structures of Compounds **30**--**38**.
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Chemical structures of Compounds **39**--**46**.
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Chemical structures of Compounds **47**--**51**.
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Chemical structures of Compounds **52**--**54**.
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###### 

Anti-neoplastic property of cyanobacterium-derived macrolides on different cell lines.

  Metabolite                                     Source                                       Location                    Target Cell Lines                                                  Concentration/Effect                                    Reference
  ---------------------------------------------- -------------------------------------------- --------------------------- ------------------------------------------------------------------ ------------------------------------------------------- ---------------------------------
  lyngbyabellin A (**1**)                        *Lyngbya majuscula*                          Guam                        KB cells and LoVo cells                                            IC~50~ value of 0.03 and 0.50 µg/mL respectively        \[[@B6-marinedrugs-15-00126]\]
  lyngbyabellin B (**2**)                        *Lyngbya majuscula*                          Guam                        KB cells and LoVo cells                                            IC~50~ value of 0.10 and 0.83 µg/mL respectively        \[[@B10-marinedrugs-15-00126]\]
  lyngbyabellin E (**3**)                        *Lyngbya majuscula*                          Papua New Guinea            NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells   LC~50~ value of 0.4 and 1.2 µM respectively             \[[@B11-marinedrugs-15-00126]\]
  lyngbyabellin F (**4**)                        *Lyngbya majuscula*                          Papua New Guinea            NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells   LC~50~ value of 1.0 and 1.8 µM respectively             \[[@B11-marinedrugs-15-00126]\]
  lyngbyabellin G (**5**)                        *Lyngbya majuscula*                          Papua New Guinea            NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells   LC~50~ value of 2.2 and 4.8 µM respectively             \[[@B11-marinedrugs-15-00126]\]
  lyngbyabellin H (**6**)                        *Lyngbya majuscula*                          Papua New Guinea            NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells   LC~50~ value of 0.2 and 1.4 µM respectively             \[[@B11-marinedrugs-15-00126]\]
  lyngbyabellin I (**7**)                        *Lyngbya majuscula*                          Papua New Guinea            NCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cells   LC~50~ value of 1.0 and 0.7 µM respectively             \[[@B11-marinedrugs-15-00126]\]
  lyngbyabellin N (**10**)                       *Moorea bouillonii*                          Palmyra Atoll, USA          H-460 human lung carcinoma and HCT116 colon cancer cell lines      IC~50~ value of 0.0048--1.8 µM and 15 µM respectively   \[[@B12-marinedrugs-15-00126]\]
  lyngbyaloside B (**13**)                       *Lyngbya* sp.                                Palau                       KB cells and LoVo cells                                            IC~50~ value of 4.3 and 15 µM respectively              \[[@B13-marinedrugs-15-00126]\]
  2-*epi*-lyngbyalosid (**14**)                  *Lyngbya bouillonii*                         Apra Harbor, Guam           HT29 colorectal adenocarcinoma and HeLa cells                      IC~50~ value of 38 and 33 µM respectively               \[[@B14-marinedrugs-15-00126]\]
  18*E*-lyngbyaloside C (**15**)                 *Lyngbya bouillonii*                         Apra Harbor, Guam           HT29 colorectal adenocarcinoma and HeLa cells                      IC~50~ value of 13 and 9.3 µM respectively              \[[@B14-marinedrugs-15-00126]\]
  18*Z*-lyngbyaloside C (**16**)                 *Lyngbya bouillonii*                         Apra Harbor, Guam           HT29 colorectal adenocarcinoma and HeLa cells                      IC~50~ value of \>100 µM and 53 µM respectively         \[[@B14-marinedrugs-15-00126]\]
  biselyngbyaside (**17**)                       *Lyngbya* sp.                                Tokunoshima Island, Japan   HeLa S~3~ cells                                                    IC~50~ value of 0.1 μg/mL                               \[[@B15-marinedrugs-15-00126]\]
  biselyngbyaside B (**18**)                     *Lyngbya* sp.                                Tokunoshima Island, Japan   HeLa S~3~ cells and HL60 cells                                     IC~50~ value of 3.5 and 0.82 µM respectively            \[[@B16-marinedrugs-15-00126]\]
  biselyngbyaside E (**21**)                     *Lyngbya* sp.                                Ishigaki Island, Japan      HeLa and HL60 cells                                                IC~50~ value of 0.19 and 0.071 µM respectively          \[[@B17-marinedrugs-15-00126]\]
  biselyngbyaside F (**22**)                     *Lyngbya* sp.                                Ishigaki Island, Japan      HeLa and HL60 cells                                                IC~50~ value of 3.1 and 0.66 µM respectively            \[[@B17-marinedrugs-15-00126]\]
  biselyngbyolide A (**23**)                     *Lyngbya* sp.                                Tokunoshima Island, Japan   HeLa S~3~ cells and HL60 cells                                     IC~50~ value of 0.22 and 0.027 µM respectively          \[[@B18-marinedrugs-15-00126]\]
  biselyngbyolide B (**24**)                     *Lyngbya* sp.                                Ishigaki Island, Japan      HeLa S~3~ cells and HL60 cells                                     IC~50~ value of 0.028 and 0.0027 µM respectively        \[[@B19-marinedrugs-15-00126]\]
  caylobolide A (**25**)                         *Lyngbya majuscula*                          Bahamian                    human colon tumor cells HCT 116                                    IC~50~ values of 9.9 µM                                 \[[@B20-marinedrugs-15-00126]\]
  caylobolide B (**26**)                         *Phormidium* spp.                            Florida USA                 HT29 colorectal adenocarcinoma and HeLa cervical carcinoma cells   IC~50~ value of 4.5 and 12.2 µM respectively            \[[@B21-marinedrugs-15-00126]\]
  swinholide A (**27**)                          *Symploca cf.* sp.                           Fiji                        several cancer cell lines                                          IC~50~ values of 0.37 nM--1.0 µM                        \[[@B22-marinedrugs-15-00126]\]
  ankaraholide A (**28**)                        *Geitlerinema* sp.                           Madagascar                  NCI-H460, Neuro-2a cells and MDA-MB-435 cells                      IC~50~ value of 119, 262 and 8.9 nM respectively        \[[@B22-marinedrugs-15-00126]\]
  scytophycin A (**30**)                         *Scytonema pseudohofmanni*                   Oahu, Hawaii                human carcinoma of nasopharynx Cell (KB cells)                     IC~50~ value of 1 ng/mL                                 \[[@B23-marinedrugs-15-00126]\]
  scytophycin B (**31**)                         *Scytonema pseudohofmanni*                   Oahu, Hawaii                KB cells                                                           IC~50~ value of 1 ng/mL                                 \[[@B23-marinedrugs-15-00126]\]
  scytophycins C-E (**32**--**34**)              *Scytonema pseudohofmanni*                   Oahu, Hawaii                KB cells                                                           IC~50~ value of 10--100 ng/mL                           \[[@B23-marinedrugs-15-00126]\]
  6-hydroxyscytophycin B (**35**)                *Scytonema mirabile*                         cultured                    KB cells and LoVo cells                                            MICs of 1--5 and 10--50 ng/mL respectively              \[[@B23-marinedrugs-15-00126]\]
  19-*O*-demethylscytophycin C (**36**)          *Scytonema burmanicurn*                      cultured                    KB cells and LoVo cells                                            MICs of 1--5 and 10--50 ng/mL respectively              \[[@B23-marinedrugs-15-00126]\]
  6-hydroxy-7-*O*-methylscytophycin E (**37**)   *Scytonema ocellatum*                        cultured                    KB cells and LoVo cells                                            MICs of 1--5 and 10--50 ng/mL respectively              \[[@B23-marinedrugs-15-00126]\]
  tolytoxin (**38**)                             *Tolypothrix conglutinata* var. *colorata*   Fanning Island              KB cells and LoVo cells                                            IC~50~ value of 8.4 and 5.3 nM respectively             \[[@B24-marinedrugs-15-00126]\]
  debromoaplysiatoxin (**39**)                   *Lyngbya majuscula*                          Marshall Islands            P-388 lymphocytic mouse leukemia                                   weak                                                    \[[@B25-marinedrugs-15-00126]\]
  lyngbouilloside (**44**)                       *Lyngbya bouillonii*                         Papua New Guinea            neuroblastoma cells                                                IC~50~ value of 17 µM                                   \[[@B26-marinedrugs-15-00126]\]
  koshikalide (**45**)                           *Lyngbya* sp.                                Mie Prefecture              HeLa S~3~ cells                                                    IC~50~ value of 42 µg/mL                                \[[@B27-marinedrugs-15-00126]\]
  sanctolide A (**46**)                          *Oscillatoria sancta*                        cultured                    HT-29 and MDA-MB-435 cell lines                                    nd ^a^                                                  \[[@B28-marinedrugs-15-00126]\]
  acutiphycin (**47**)                           *Oscillatoria acutissima*                    Manoa Valley Oahu, Hawaii   KB cells and NIH/3T3 cells                                         ED~50~ \< 1 µg/mL                                       \[[@B29-marinedrugs-15-00126]\]
  20,21-didehydroacutiphycin (**48**)            *Oscillatoria acutissima*                    Manoa Valley Oahu, Hawaii   KB cells and NIH/3T3 cells                                         ED~50~ \< 1 µg/mL                                       \[[@B29-marinedrugs-15-00126]\]
  polycavernoside D (**49**)                     *Okeania* sp.                                Puerto Rican                H-460 human lung cancer cell lines                                 EC~50~ value of 2.5 µM                                  \[[@B30-marinedrugs-15-00126]\]
  bastimolide A (**50**)                         *Okeania hirsuta*                            Panama                      Vero cells                                                         IC~50~ value of 2.1 µM                                  \[[@B31-marinedrugs-15-00126]\]
  nuiapolide (**51**)                            colonial cyanobacterium (071905-NII-01)      Hawaii                      Jurkat cells and cancerous T lymphocytes                           anti-chemotactic activity                               \[[@B32-marinedrugs-15-00126]\]

**^a^** Not determined.

marinedrugs-15-00126-t002_Table 2

###### 

Antibacterial and antifungal macrolides.

  Metabolite                                     Source                                       Location         Target                                                                                                            Concentration/Effect                                                                         Reference
  ---------------------------------------------- -------------------------------------------- ---------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------
  6-hydroxyscytophycin B (**35**)                *Scytonema mirabile*                         cultured         Fungus (1) *Aspergillus oryzae* (2) *Candida albicans* (3) *Penicillium notatum* (4) *Saccharomyces cerevisiae*   nd ^a^                                                                                       \[[@B23-marinedrugs-15-00126]\]
  19-*O*-demethylscytophycin C (**36**)          *Scytonema burmanicurn*                      cultured         Fungus (1) *Aspergillus oryzae* (2) *Candida albicans* (3) *Penicillium notatum* (4) *Saccharomyces cerevisiae*   nd ^a^                                                                                       \[[@B23-marinedrugs-15-00126]\]
  6-hydroxy-7-*O*-methylscytophycin E (**37**)   *Scytonema ocellatum*                        cultured         Fungus (1) *Aspergillus oryzae* (2) *Candida albicans* (3) *Penicillium notatum* (4) *Saccharomyces cerevisiae*   nd ^a^                                                                                       \[[@B23-marinedrugs-15-00126]\]
  tolytoxin (**38**)                             *Tolypothrix conglutinata* var. *colorata*   Fanning Island   Fungi *Penicillium notatum* and *Rhizoctonia solani* 1165                                                         MIC value of 0.25 nM respectively                                                            \[[@B24-marinedrugs-15-00126]\]
  7-OMe-scytophycin B (**52**)                   *Anabaena* sp.                               cultured         Fungus *Candida albicans* HAMBI 484 and *Candida guilliermondii* HAMBI 257                                        MIC values of 0.40 and 0.80 mM respectively; IC~50~ value of 0.19 and 0.23 µM respectively   \[[@B45-marinedrugs-15-00126]\]
  amantelide A (**53**)                          Oscillatoriales                              Guam             Fungi *Lindra thalassiae* and *Fusarium* sp.                                                                      totally inhibited of 62.5 μg/mL                                                              \[[@B46-marinedrugs-15-00126]\]
  amantelide B (**54**)                          Oscillatoriales                              Guam             Fungus *Dendryphiella salina*                                                                                     totally inhibited of 6.25 μg/mL                                                              \[[@B46-marinedrugs-15-00126]\]

**^a^** Not determined.

marinedrugs-15-00126-t003_Table 3

###### 

Effects of cyanobacterium-derived macrolides on animals.

  Metabolite                Source                       Location                 Target Fauna                           Impacts                          Reference
  ------------------------- ---------------------------- ------------------------ -------------------------------------- -------------------------------- ---------------------------------
  lyngbyabellin A (**1**)   *Lyngbya majuscula*          Guam                     mice                                   LD~50~ value of 1.2--1.5 mg/kg   \[[@B6-marinedrugs-15-00126]\]
  tolytoxin (**38**)        *Scytonema pseudohofmanni*   cultured                 mice                                   LD~50~ value of 1.5 mg/kg        \[[@B24-marinedrugs-15-00126]\]
  sanctolide A (**48**)     *Oscillatoria sancta*        cultured                 brine shrimp                           LD~50~ value of 23.5 μM          \[[@B28-marinedrugs-15-00126]\]
  gloeolactone (**55**)     *Gloeotrichia* sp.           Clark Canyon Reservoir   brine shrimp                           100% killed at 125 µg/mL         \[[@B48-marinedrugs-15-00126]\]
  phormidolide (**56**)     *Phormidium* sp.             Sulawesi, Indonesia      brine shrimp                           LD~50~ value of 1.5 μM           \[[@B49-marinedrugs-15-00126]\]
  cyanolide A (**57**)      *Lyngbya bouillonii*         Papua New Guinea         snail vector *Biomphalaria glabrata*   LD~50~ value of 1.2 μM           \[[@B50-marinedrugs-15-00126]\]

marinedrugs-15-00126-t004_Table 4

###### 

Other bioactivity of cyanobacterium-derived macrolides.

  Metabolite                     Source                                Location                           Biological Activity                                                                                                                                              Reference
  ------------------------------ ------------------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  biselyngbyaside (**17**)       *Lyngbya* sp.                         Okinawa Prefecture Japan           osteoclast differentiation and function                                                                                                                          \[[@B52-marinedrugs-15-00126]\]
  debromoaplysiatoxin (**39**)   *Lyngbya majuscula*                   Enewetak Atoll, Marshall Islands   produce an irritant pustular folliculitis in humans and cause a severe cutaneous inflammatory reaction in the rabbit and in hairless mice                        \[[@B25-marinedrugs-15-00126]\]
  bastimolide A (**50**)         *Okeania hirsuta*                     Caribbean coast of Panama          *Plasmodium falciparum* TM90-C2A, TM90-C2B, W2, TM91-C235 (IC~50~ values of 80, 90, 140 and 270 nM respectively)                                                 \[[@B31-marinedrugs-15-00126]\]
  malyngolide dimer (**58**)     *Lyngbya majuscula*                   Panama                             *Plasmodium falciparum* (IC~50~ values of 19 µM)                                                                                                                 \[[@B53-marinedrugs-15-00126]\]
  tanikolide dimer (**59**)      *Lyngbya majuscula*                   Madagascar                         SIRT2 (IC~50~ = 176 nM to 2.4 µM)                                                                                                                                \[[@B54-marinedrugs-15-00126]\]
  palmyrolide A (**60**)         *Leptolyngbya cf. Oscillatoria* sp.   Palmyra Atoll                      suppression of calcium influx in cerebrocortical neurons (IC~50~ value of 3.70 µM) sodium channel blocking activity in neuro-2a cells (IC~50~ value of 5.2 µM)   \[[@B55-marinedrugs-15-00126]\]
  cocosolide (**61**)            *Symploca* sp.                        Guam                               inhibition of IL-2 production and T-cell proliferation                                                                                                           \[[@B7-marinedrugs-15-00126]\]
